| NCT ID | NCT05224726 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Cesarean Section Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-19 |
| Primary Completion | 2028-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-19 with a primary completion date of 2028-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.
Eligibility Criteria
Inclusion criteria: * Women undergoing elective cesarean delivery * Term pregnancy (≥37 weeks of gestation) Exclusion criteria: * Thrombocytopenia (CBC Platelet count \<70,000) * Connective tissue disease * Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection) * Malformed uterus (unicornuate, bicornuate, didelphic)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05224726 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 52 Years, studying Cesarean Section Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05224726 currently recruiting?
Yes, NCT05224726 is actively recruiting participants. Contact the research team at mohraya@gmail.com for enrollment information.
Where is the NCT05224726 trial being conducted?
This trial is being conducted at Ramat Gan, Israel.
Who is sponsoring the NCT05224726 clinical trial?
NCT05224726 is sponsored by The University of Texas Health Science Center, Houston. The trial plans to enroll 40 participants.